Literature DB >> 34284995

Triple Therapy to Outwit the BRAF Oncogene.

Chao Zhang1, Gideon Bollag1.   

Abstract

BRAF-mutant cancers have been knocked down by BRAF and MEK inhibitor combos, yet the cancers always find a way to get back up. Adding a third medicine, namely, a dimer-selective BRAF inhibitor, can knock down longer and better.See related article by Adamopoulos et al., p. 1716. ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34284995     DOI： 10.1158/2159-8290.CD-21-0378

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  2 in total

1.  Computational Model of Heterogeneity in Melanoma: Designing Therapies and Predicting Outcomes.

Authors:  Arran Hodgkinson; Dumitru Trucu; Matthieu Lacroix; Laurent Le Cam; Ovidiu Radulescu
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

2.  RNA-binding protein ZCCHC4 promotes human cancer chemoresistance by disrupting DNA-damage-induced apoptosis.

Authors:  Ha Zhu; Kun Chen; Yali Chen; Juan Liu; Xiaomin Zhang; Yumei Zhou; Qiuyan Liu; Bingjing Wang; Taoyong Chen; Xuetao Cao
Journal:  Signal Transduct Target Ther       Date:  2022-07-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.